Digital Therapeutics Market Size & Share 2026-2035

Digital Therapeutics Market Size

The global digital therapeutics market was valued at USD 9.6 billion in 2025. The market is expected to grow from USD 12 billion in 2026 to USD 93.4 billion in 2035, at a CAGR of 25.6% during the forecast period according to the latest report published by Global Market Insights Inc.

The growth is primarily driven by the rising global burden of chronic diseases, including diabetes, cardiovascular disorders, and mental health conditions, which has increased the demand for innovative disease management solutions. Digital therapeutics (DTx) offer scalable, cost-effective, and personalized treatment approaches, making them increasingly attractive to healthcare providers, payers, and patients.

The growing integration of advanced technologies such as artificial intelligence (AI), machine learning (ML), mobile applications, wearable devices, and gamification features is further enhancing the effectiveness and personalization of digital therapeutics. These technological advancements improve patient engagement, treatment adherence, and clinical outcomes, thereby accelerating market adoption. For example, according to the U.S. Food and Drug Administration (FDA), the number of AI/ML-enabled medical devices receiving marketing authorization increased from 29 in 2021 to 91 in 2022.

Digital therapeutics are evidence-based software solutions designed to prevent, manage, or treat medical conditions through clinically validated interventions. Delivered through platforms such as mobile applications, web-based tools, and virtual reality experiences, these solutions are regulated similarly to medical devices and are increasingly becoming an integral part of modern healthcare delivery.

Key market participants, including Otsuka Holdings, Virta Health, and Omada Health Inc., continue to strengthen their market presence through the development of clinically validated digital interventions, strategic collaborations with healthcare providers and payers, and substantial investments in research, technology innovation, and regulatory approvals.

Digital therapeutics also contribute to healthcare cost reduction by minimizing hospital visits and enabling remote patient monitoring. According to the Centers for Medicare & Medicaid Services (CMS), U.S. healthcare spending reached USD 4.3 trillion in 2021, with digital health solutions having the potential to reduce healthcare expenditures by up to 20%. Additionally, the FDA approved 132 digital therapeutics solutions in 2022, representing a 45% increase compared to 2021.

Furthermore, a 2023 report by McKinsey estimates that digital therapeutics could generate approximately USD 23 billion in annual healthcare savings by 2025 through reduced hospital readmissions and enhanced remote monitoring capabilities. Compared with conventional treatment approaches, digital therapeutics offer greater affordability and accessibility, particularly through smartphone-based applications.

The market has demonstrated robust growth in recent years, expanding from USD 4.4 billion in 2022 to USD 7.7 billion in 2024. Increasing regulatory support and recognition from governments and healthcare authorities are further driving adoption. For instance, Germany's Digital Healthcare Act has enabled physicians to prescribe digital therapeutics, thereby improving their credibility and market acceptance. As of 2023, the German Federal Institute for Drugs and Medical Devices (BfArM) had approved 48 Digital Health Applications (DiGA) for prescription use, contributing significantly to market expansion.

Additionally, growing investments from venture capital firms and technology companies in digital therapeutics startups are fostering innovation across the sector. Strategic partnerships between pharmaceutical companies and digital health firms are accelerating product development, expanding market reach, and creating new opportunities for industry growth.

Digital Therapeutics Market Trends

• The digital therapeutics industry is anticipated to experience substantial growth, driven by the increasing adoption of software-based interventions for chronic disease management, rising demand for personalized and data-driven treatment solutions, expanding regulatory support for clinically validated digital therapies, and the growing integration of telehealth platforms and wearable technologies. Continuous advancements in artificial intelligence (AI), machine learning, and patient engagement tools are further accelerating market expansion.
• The growing prevalence of chronic diseases, including diabetes, cardiovascular disorders, and mental health conditions, is significantly increasing the demand for digital therapeutics. These solutions provide scalable, cost-effective, and personalized approaches to disease management, creating value for both healthcare providers and patients.
• According to the American Heart Association (2023), cardiovascular diseases affect nearly 48% of adults in the U.S., while the World Health Organization estimates that depression impacts approximately 280 million people worldwide. Reflecting this growing need, digital therapeutics companies such as Livongo Health reported a 168% year-over-year increase in diabetes management enrollment, underscoring the rapid adoption of digital health solutions for chronic disease care.
• The increasing emphasis on early intervention and lifestyle modification is also expanding the role of digital therapeutics in preventive healthcare, particularly for metabolic and neurological disorders. In 2023, Omada Health reported that its preventive digital care program reduced the risk of type 2 diabetes by 30% among high-risk individuals.
• Furthermore, data from the National Institute of Mental Health (NIMH) indicate that more than 21% of U.S. adults experience mental illness, contributing to the growing adoption of preventive digital mental health solutions.
• The market is increasingly extending beyond traditional healthcare settings through direct-to-consumer models and employer-sponsored wellness programs. According to the National Business Group on Health, 76% of employers planned to incorporate digital therapeutics into their employee wellness initiatives.
• Digital therapeutic platforms targeting mental health conditions, attention-deficit/hyperactivity disorder (ADHD), and behavioral disorders are witnessing robust growth, supported by increasing mental health awareness and widespread smartphone penetration. The National Institute of Mental Health reported that mental health app usage increased by 47%, with nearly 38 million Americans regularly using at least one mental health application.
• Technological innovations, including smart inhalers, microneedle patches, and targeted-release drug delivery devices, are enhancing treatment precision and minimizing side effects. Additionally, virtual replicas of human physiology, often referred to as digital twins, are increasingly being used to simulate drug responses and optimize therapeutic design.
• Regulatory acceptance of Real-World Evidence (RWE) and randomized clinical trials is further strengthening the clinical credibility and reimbursement potential of digital therapeutics products.
• Cloud-based platforms are enabling efficient data hosting, analytics, and remote software updates, thereby reducing infrastructure costs and improving accessibility. For instance, the International Data Corporation (IDC) forecasts that global spending on public cloud services and infrastructure will reach USD 1.3 trillion by 2025, creating a supportive ecosystem for the expansion of digital therapeutics.

Digital Therapeutics Market Analysis

Based on component, the digital therapeutics market is divided into software, hardware and services. The software segment has asserted its dominance in the market by securing a significant market share of 54.4% in 2025 driven by the increasing adoption of clinically validated mobile and cloud-based therapeutic solutions, ease of accessibility, and seamless integration with connected devices and telehealth platforms. The segment is expected to exceed USD 51.6 billion by 2035, growing at a CAGR of 25.8% during the forecast period.

• Digital therapeutics software enables highly personalized treatment plans through the use of patient data, artificial intelligence (AI), and behavioral science. These platforms support long-term behavior modification, improve medication adherence, and enhance chronic disease management, making personalized care a key driver of software adoption.
• Software-based DTx solutions offer high scalability and can be accessed through smartphones, tablets, and computers. This accessibility allows healthcare providers to extend care to remote and underserved populations, reducing reliance on in-person visits and improving healthcare delivery.
• The hardware segment is anticipated to register a CAGR of 25.1% during the forecast period. Growth in this segment is supported by the increasing adoption of connected medical devices and hardware-integrated DTx solutions that are receiving regulatory approvals, including those from the FDA and CE authorities, thereby enhancing provider and patient confidence.
• The services segment is projected to grow at a CAGR of 25.7% during the analysis period. Rising demand for integrated support services, such as patient monitoring, health coaching, technical assistance, and data analytics, is driving segment growth by improving treatment adherence and clinical outcomes.

Based on the application, the digital therapeutics market is segmented into diabetes, obesity, cardiovascular, mental & behavior health, hypertension, insomnia and other applications. The diabetes segment dominated the market in 2025 with a revenue of USD 2.8 billion.

• The rising incidence of Type 1 diabetes, Type 2 diabetes, and gestational diabetes-driven by aging populations, sedentary lifestyles, and unhealthy dietary habits-is increasing demand for effective disease management solutions. Digital therapeutics provide personalized and non-invasive interventions that help patients monitor glucose levels, adhere to medication regimens, and adopt healthier lifestyles.
• Technological advancements in mobile applications, wearable sensors, AI-powered analytics, and cloud-based platforms have significantly transformed diabetes management. These technologies enable real-time monitoring, predictive insights, and personalized behavioral coaching, improving glycemic control and reducing disease-related complications.
• Their integration into digital therapeutics platforms enhances usability, patient engagement, and clinical outcomes, thereby supporting wider adoption across healthcare systems.
• The cardiovascular segment accounted for a substantial share of market revenue in 2025 and is expected to grow at a CAGR of 26.1% over the forecast period. Rising prevalence of cardiovascular diseases due to aging populations, sedentary lifestyles, and poor dietary habits is increasing demand for scalable and non-invasive digital health solutions.
• The mental and behavioral health segment also accounted for a notable revenue share in 2025 and is expected to register a CAGR of 25.5% during the forecast period. Increasing prevalence of mental health disorders, growing acceptance of digital cognitive behavioral therapy (CBT), and rising demand for accessible treatment options are supporting market growth.

• Healthcare providers are increasingly incorporating digital therapeutics into clinical workflows to monitor patient progress, optimize treatment plans, and improve care delivery. Real-time data analytics, predictive insights, and personalized interventions enable clinicians to make more informed decisions and enhance patient outcomes.
• Healthcare providers place significant importance on DTx solutions supported by robust clinical evidence and regulatory approvals, such as those granted by the FDA and CE authorities. These validations ensure safety, efficacy, and reliability, increasing physician confidence in prescribing digital therapies.
• Many DTx platforms incorporate features such as gamification, reminders, and interactive interfaces to improve patient engagement and adherence. Enhanced communication, continuous monitoring, and improved treatment compliance contribute to better clinical outcomes and higher patient satisfaction.
• The payers segment accounted for a substantial share of revenue in 2025 and is projected to grow at a CAGR of 25.9% during the forecast period. Growth is driven by increasing adoption of digital therapeutics by insurance providers and payers to reduce healthcare costs, improve population health outcomes, and support value-based care models.
• The patients segment also generated significant revenue in 2025 and is expected to expand at a CAGR of 25.4% over the forecast period. Increasing awareness of digital health solutions, growing preference for convenient and accessible treatment options, and rising demand for personalized care are key factors supporting segment growth.

North America Digital Therapeutics Market

The North America digital therapeutics industry dominated 58.1% of revenue share in 2025.

• The U.S. market was valued at USD 2.3 billion and USD 3.1 billion in 2022 and 2023, respectively. The market size reached USD 5.1 billion in 2025, growing from USD 4.1 billion in 2024.

• North America bears a substantial burden of chronic diseases, including diabetes, cardiovascular disorders, and mental health conditions. This has increased the demand for scalable, non-invasive digital therapies that provide continuous monitoring, personalized interventions, and improved disease management.
• Large employers across North America are increasingly incorporating digital therapeutics into corporate wellness programs to improve employee health outcomes, reduce absenteeism, and lower healthcare expenditures. This trend is expanding DTx adoption beyond traditional clinical settings.
• The U.S. accounts for more than 90% of the North American digital therapeutics market, driven by the early adoption of telemedicine, mobile health applications, and connected medical devices. The country's leadership in digital health innovation continues to establish regulatory and reimbursement benchmarks for the region.
• Furthermore, the U.S. Food and Drug Administration (FDA) has established regulatory pathways for Software as a Medical Device (SaMD), including digital therapeutics. Temporary regulatory flexibilities introduced during the COVID-19 pandemic further accelerated acceptance, particularly for mental health applications, thereby supporting market growth.

Europe Digital Therapeutics Market

Europe digital therapeutics industry accounted for USD 1.9 billion in 2025 and is anticipated to show lucrative growth over the forecast period.

• European governments and regulatory agencies are actively promoting digital health adoption. Germany's Digital Healthcare Act (DVG), which enables reimbursement for approved digital therapeutics applications, has established a strong framework for broader DTx adoption across the region.
• Europe's rapidly aging population is increasing the demand for continuous care and chronic disease management solutions. According to Eurostat, the share of the EU-27 population aged 65 years and above is projected to rise significantly, driving demand for innovative healthcare technologies.
• The European Commission estimates that chronic diseases affect nearly 60% of individuals aged over 65 years in Europe, with many patients experiencing multiple comorbidities. As a result, digital therapeutics provide accessible, home-based care solutions that address the complex healthcare needs of elderly populations.
• The increasing adoption of remote monitoring technologies further supports market expansion. For example, ResMed reported a significant increase in elderly users across Europe utilizing digital therapeutic solutions for chronic disease management and remote patient monitoring.

Asia Pacific Digital Therapeutics Market

The Asia Pacific digital therapeutics industry is anticipated to grow at the highest CAGR of 26% during the analysis timeframe.

• The region is experiencing a rapid rise in lifestyle-related disorders, including diabetes, hypertension, obesity, and mental health conditions. Digital therapeutics offer scalable, remote, and cost-effective solutions for disease management, particularly in underserved and rural areas.
• Countries such as Japan, South Korea, and China are actively developing regulatory pathways for digital health technologies, including digital therapeutics. These evolving regulatory frameworks are strengthening stakeholder confidence and facilitating market entry.
• Increasing smartphone penetration, expanding internet connectivity, and growing investments in digital healthcare infrastructure are further supporting market growth across the region.
• Regional innovators, including CureApp in Japan and Wellthy Therapeutics in India, are developing culturally tailored, AI-enabled digital therapeutic solutions, thereby accelerating adoption across diverse patient populations.

Latin American Digital Therapeutics Market

The Latin America uterine digital therapeutics industry is experiencing robust growth over the analysis timeframe.

• Countries such as Brazil and Mexico are witnessing a growing prevalence of chronic diseases, including diabetes, cardiovascular disorders, and obesity. Digital therapeutics provide scalable and cost-effective solutions for disease management, particularly in underserved and remote regions.
• Expanding smartphone penetration and improving internet accessibility are creating favorable conditions for adoption of digital health throughout the region.
• In Brazil, increasing adoption of AI-powered healthcare platforms is enhancing treatment personalization, patient adherence, and remote monitoring capabilities, thereby supporting broader adoption of digital therapeutics.

Middle East and Africa Digital Therapeutics Market

The Middle East & Africa (MEA) market is experiencing robust growth over the analysis timeframe.

• Countries across the region, particularly Saudi Arabia, are experiencing a rising burden of chronic diseases such as diabetes, cardiovascular disorders, and obesity due to changing lifestyles and urbanization. Digital therapeutics provide scalable and non-invasive solutions for managing these conditions while reducing the burden on healthcare systems.
• The ability of digital therapeutics to deliver personalized care, enable remote monitoring, and reduce hospital visits makes them increasingly attractive in resource-constrained healthcare environments.
• Saudi Arabia's Vision 2030 initiative places significant emphasis on healthcare modernization and digital transformation. Government-backed platforms such as Sehha and Tawakkalna are promoting digital health adoption and creating a favorable ecosystem for digital therapeutics.
• The integration of telemedicine, mobile health technologies, and artificial intelligence into public healthcare strategies is accelerating awareness, infrastructure development, and the adoption of digital therapeutics across the region.

Digital Therapeutics Market Share

The digital therapeutics industry is moderately fragmented, with a mix of specialized digital therapeutics providers, digital health platforms, and pharmaceutical-backed players competing across therapeutic areas. Companies compete on clinical validation, regulatory approvals, user engagement, and scalability of business models, while leveraging partnerships with employers, payers, and healthcare providers to expand adoption. Key players include Omada Health, Teladoc Health, Click Therapeutics, Akili Interactive, and Big Health, collectively account for 75% share of the market.

The competitive landscape is evolving rapidly following the collapse of early prescription digital therapeutics models, leading to a shift toward evidence-based, commercially scalable solutions. Market participants are increasingly focusing on expanding their offerings through chronic disease management programs, mental health solutions, and AI-driven platforms. Strategic initiatives such as partnerships with pharmaceutical companies, employer-sponsored programs, and geographic expansion are further intensifying competition and strengthening market positioning.

Digital Therapeutics Market Companies

Prominent players operating in the digital therapeutics industry are as mentioned below:

• AmerisourceBergen
• Akili Interactive
• Better Therapeutics
• Big Health
• Click Therapeutics
• DarioHealth
• Kaia Health
• Omada Health
• Orexo
• Otsuka Holdings
• Propeller Health
• Sidekick Health
• Teladoc Health
• Virta Health
• WellDoc

• Omada Health

Demonstrates strong leadership in digital therapeutics through scalable chronic disease management programs, particularly in diabetes and cardiovascular health. Its data-driven coaching model combined with deep employer and payer integration enables improved clinical outcomes while reducing overall healthcare costs.

• Teladoc Health

Operates as a dominant virtual care platform integrating digital therapeutics with remote monitoring and chronic condition management. Its extensive global footprint, broad service portfolio, and strong payer relationships support large-scale adoption across multiple therapeutic areas.

• Click Therapeutics

Specializes in prescription digital therapeutics with a focus on clinically validated, software-based treatments. Strategic partnerships with pharmaceutical companies and a robust clinical pipeline position the company as a key innovator in evidence-based digital therapeutics.

Digital Therapeutics Market Industry News

• In February 2025, Hyfe, the global leader in AI-powered respiratory care, announces its partnership with KYORIN Pharmaceutical Co. Ltd for the development and commercialization of the world’s first prescription digital therapeutic (DTx) to treat chronic cough in the Japanese market.
• In April 2025, Click Therapeutics, a leader in prescription medical treatments as both prescription digital therapeutics and software-enhanced drug therapies, obtained FDA marketing authorization for the first prescription digital therapeutic for the preventive treatment of episodic migraine. FDA granted the De Novo Classification Request for the company’s prescription digital therapeutic, CT-132, for the preventive treatment of episodic migraine in patients 18 years of age and older.
• In January 2023, Lupin Digital Health, a wholly owned subsidiary of global pharma major Lupin Limited, today announced the launch of its digital therapeutics’ solution, LYFE. LYFE is India’s only evidence-based holistic heart care programme that significantly reduces the risk of a heart attack and improves vitals and quality of life for cardiac patients.

The digital therapeutics market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2022 - 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Component

• Software
  • On-premise
  • Cloud-based
• Hardware
  • Wearable devices
  • Sensors and monitoring devices
  • Other devices
• Services
  • Consulting and integration
  • Training and education
  • Other services  

Market, By Application

• Diabetes
• Obesity
• Cardiovascular
• Mental and behavior Health
• Hypertension
• Insomnia
• Other applications

Market, By End Use

• Healthcare providers
  • Hospitals
  • Clinics
  • Telehealth platforms
• Payers
• Patients
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea

• Latin America
  • Brazil
  • Mexico
  • Argentina

• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE